On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...